OBJECTIVES: Several analyses on treatment dynamics in Alzheimer’s disease (AD) using claims data have been published, but there is little similar data available in Dementia with Lewy Bodies (DLB). This study seeks to characterize DLB treatment dynamics using data from a claims database. METHODS: Truven MarketScan, a US claims database with over 100 million patients, was used for this study. Two samples were identified for analysis: “cross-sectional” (Jul 2014–Jun 2015) and “longitudinal” (Jan 2010–Jun 2015). Both cohorts used similar inclusion criteria, though patients in the longitudinal cohort were tracked from their first dementia diagnosis (Dx) whereas patients in the cross-sectional cohort were identified based on a combination of ICD-9 diagnostic, confirmatory diagnostic and/or treatment (Rx) claims. RESULTS: For the cross-sectional analysis, 26,315 AD and 473 DLB patients were identified. The mean ages were 83 (AD) and 81 (DLB) years. AD patients were more frequently female (63% v. 52%). For the longitudinal analysis, 16,107 AD and 771 DLB patients were identified. The mean age for both AD and DLB was 81 years. AD patients were more often female than DLB patients (63% v. 53%). Despite more specialist involvement, the DLB patients were less likely to be taking dementia Rx than AD patients (69% v. 77%) and those on Rx were more likely to be on monotherapy. DLB patients had higher use of psychotropic Rx. Setting of care was similar, but the DLB group had higher annualized costs, driven by hospitalization. CONCLUSIONS: The gender and psychotropic use characteristics of the DLB patients identified in this analysis are consistent with the diagnosis of DLB. The results suggest that DLB patients have more annualized cost and are on more psychotropic medications than AD patients, but surprisingly are less frequently on dementia Rx.